HALO•benzinga•
Halozyme Therapeutics Sees FY24 Adj. EPS $4.00-$4.20 To $3.96 Est.; Revenue $970M-$1.020B Vs $983.852M Est.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on October 31, 2024 by benzinga